Plasma pentraxin-3 is associated with endothelial dysfunction in non-alcoholic fatty liver disease


Gurel H., Genc H., Celebi G., Sertoglu E., Cicek A. F. , KAYADİBİ H., ...More

EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, vol.20, no.20, pp.4305-4312, 2016 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 20 Issue: 20
  • Publication Date: 2016
  • Journal Name: EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.4305-4312
  • Keywords: Pentraxin-3, Endothelial dysfunction, Non-alcoholic fatty liver disease, HOMEOSTASIS MODEL ASSESSMENT, C-REACTIVE PROTEIN, STEATOHEPATITIS NASH, CARDIOVASCULAR RISK, OBESITY, SENSITIVITY, ACTIVATION, SEVERITY, GLUCOSE, PTX3
  • Eskisehir Osmangazi University Affiliated: No

Abstract

OBJECTIVE: Pentraxin-3 (PTX3) is an acute-phase protein belonging to the PTX family. It has been reported that PTX-3 is significantly associated with obesity, metabolic syndrome, and cardiovascular diseases (CVD). Non-alcoholic fatty liver disease (NAFLD) is strongly associated with atherosclerosis and CVD. In this study, we aimed to investigate the relationship of PTX-3 with circulating markers of endothelial dysfunction and atherosclerosis in patients with NAFLD.